{"id":"biontech-pfizer-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"70–90","effect":"Injection site pain"},{"rate":"50–60","effect":"Fatigue"},{"rate":"40–50","effect":"Headache"},{"rate":"30–40","effect":"Myalgia"},{"rate":"15–25","effect":"Fever"},{"rate":"10–20","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers lipid nanoparticle-encapsulated messenger RNA encoding the spike protein of SARS-CoV-2. Once inside cells, the mRNA is translated into spike protein, which is presented to the immune system, stimulating both CD8+ T-cell and B-cell responses including neutralizing antibody production. This adaptive immune response provides protection against subsequent SARS-CoV-2 exposure.","oneSentence":"This mRNA vaccine instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response that protects against COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:34.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in individuals 6 months of age and older"},{"name":"COVID-19 booster vaccination"}]},"trialDetails":[{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT05160636","phase":"","title":"A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-01-31","conditions":"COVID-19, Coronavirus Disease 2019, Influenza","enrollment":999},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT06703190","phase":"","title":"Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"COVID-19","enrollment":1},{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05518487","phase":"PHASE2","title":"COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-02-20","conditions":"COVID-19, Kidney Transplant","enrollment":15},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05022329","phase":"PHASE2, PHASE3","title":"COVID-19 Vaccine Boosters in Patients With CKD","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-09-30","conditions":"Chronic Kidney Diseases, COVID-19","enrollment":273},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT05148962","phase":"PHASE1","title":"Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Gritstone bio, Inc.","startDate":"2021-09-16","conditions":"COVID-19","enrollment":45},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT04922944","phase":"","title":"Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients","status":"COMPLETED","sponsor":"Huntington Memorial Hospital","startDate":"2021-03-08","conditions":"Covid19, Vaccine Reaction","enrollment":167},{"nctId":"NCT06587503","phase":"PHASE4","title":"Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2024-10","conditions":"Ebola Virus Disease, COVID-19","enrollment":72},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT06429020","phase":"","title":"Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy","status":"COMPLETED","sponsor":"Chimei Medical Center","startDate":"2023-01-01","conditions":"Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population","enrollment":1089},{"nctId":"NCT04747522","phase":"","title":"Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-01-22","conditions":"Kidney Transplant Infection, SARS-CoV Infection","enrollment":150},{"nctId":"NCT05977127","phase":"PHASE2","title":"Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2023-09-26","conditions":"Vaccination; Infection, COVID-19","enrollment":48},{"nctId":"NCT05406908","phase":"PHASE4","title":"Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-06-15","conditions":"Bullous Dermatoses, Psoriasis, COVID-19 Vaccines","enrollment":109},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT06163677","phase":"","title":"A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-01-17","conditions":"COVID-19, Coronavirus Disease 2019, Influenza","enrollment":""},{"nctId":"NCT05104385","phase":"","title":"Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2021-06-21","conditions":"COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection","enrollment":1223},{"nctId":"NCT05142514","phase":"PHASE2","title":"Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-11","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":629},{"nctId":"NCT05020145","phase":"","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-25","conditions":"Immunocompromised, Immunosuppressed, Covid-19","enrollment":1277747},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT04843774","phase":"","title":"Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-04-20","conditions":"Multiple Sclerosis","enrollment":64},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05405283","phase":"PHASE3","title":"Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-08","conditions":"COVID-19 Vaccines","enrollment":189},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248},{"nctId":"NCT04664023","phase":"","title":"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2020-12-09","conditions":"Covid19","enrollment":130},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT05851313","phase":"PHASE3","title":"Role of Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response","status":"COMPLETED","sponsor":"Sulaimani Polytechnic University","startDate":"2022-12-05","conditions":"COVID-19 Respiratory Infection","enrollment":500},{"nctId":"NCT05516459","phase":"","title":"Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2022-01-06","conditions":"Coronavirus Infections","enrollment":635},{"nctId":"NCT05490108","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2022-06-02","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":60},{"nctId":"NCT05175742","phase":"PHASE2","title":"PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.","status":"COMPLETED","sponsor":"Providence Therapeutics Holdings Inc.","startDate":"2021-08-17","conditions":"Covid19 Vaccine","enrollment":565},{"nctId":"NCT04852861","phase":"PHASE4","title":"COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine","status":"COMPLETED","sponsor":"Sciensano","startDate":"2021-05-10","conditions":"Covid19","enrollment":145},{"nctId":"NCT05305573","phase":"PHASE2","title":"Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2022-03-25","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":26},{"nctId":"NCT05208983","phase":"","title":"SafeTy and Efficacy of Preventative CoVID Vaccines","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-05-06","conditions":"COVID-19 Virus Infection, Vaccine Response","enrollment":1286},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05076227","phase":"","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","status":"COMPLETED","sponsor":"Serge Thal","startDate":"2021-01-30","conditions":"SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity","enrollment":1206},{"nctId":"NCT05618548","phase":"","title":"Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2021-03-01","conditions":"Covid19","enrollment":110},{"nctId":"NCT05083065","phase":"","title":"Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine","status":"COMPLETED","sponsor":"Università degli Studi dell'Insubria","startDate":"2021-09-10","conditions":"COVID-19, Vaccine, Menstrual Irregularity","enrollment":369},{"nctId":"NCT05465863","phase":"NA","title":"Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2021-09-01","conditions":"Chronic Kidney Disease 5D, Chronic Kidney Disease 5T","enrollment":101},{"nctId":"NCT05124171","phase":"PHASE3","title":"Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-08","conditions":"COVID-19, Vaccine Reaction","enrollment":247},{"nctId":"NCT05049226","phase":"PHASE2","title":"Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-09-24","conditions":"COVID-19 Infection, COVID-19 VACCINE","enrollment":1250},{"nctId":"NCT04978038","phase":"PHASE4","title":"Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs","status":"UNKNOWN","sponsor":"Mark Loeb","startDate":"2022-08-01","conditions":"SARS-CoV2 Infection, Coronavirus Infection","enrollment":414},{"nctId":"NCT05438472","phase":"","title":"Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-12-10","conditions":"Myocarditis","enrollment":835},{"nctId":"NCT05288231","phase":"","title":"Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-11-03","conditions":"Covid-19 Vaccine","enrollment":314},{"nctId":"NCT05308680","phase":"","title":"Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2022-01-06","conditions":"Myocardial Injury, Vaccine Adverse Reaction, COVID-19","enrollment":336},{"nctId":"NCT05329064","phase":"PHASE4","title":"Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2022-03-24","conditions":"Vaccine Reaction, COVID-19, Children, Only","enrollment":150},{"nctId":"NCT04743388","phase":"","title":"Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2021-01-04","conditions":"COVID-19, Healthy Volunteers, Chronic Disease","enrollment":600},{"nctId":"NCT05315856","phase":"","title":"Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-03-01","conditions":"COVID-19 Vaccination, Inflammation, Vaccine Immune Response","enrollment":120},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05279365","phase":"PHASE2, PHASE3","title":"PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS","status":"UNKNOWN","sponsor":"DHR Health Institute for Research and Development","startDate":"2021-07-30","conditions":"SARS CoV 2 Infection, COVID-19","enrollment":1000},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05270967","phase":"","title":"FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination","status":"COMPLETED","sponsor":"Kocaeli University","startDate":"2021-07-29","conditions":"Vaccine Reaction, Oncology","enrollment":129},{"nctId":"NCT04742569","phase":"","title":"Wearable Diagnostic for Detection of COVID-19 Infection","status":"COMPLETED","sponsor":"ClinOne, Inc.","startDate":"2020-12-21","conditions":"COVID-19","enrollment":790},{"nctId":"NCT05157230","phase":"NA","title":"Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination","status":"COMPLETED","sponsor":"Bursa Yuksek Ihtisas Training and Research Hospital","startDate":"2021-09-01","conditions":"Vaccines, Adverse Effects, Injection Site Reaction","enrollment":401},{"nctId":"NCT05178264","phase":"","title":"Transverse Myelitis Related to SARS-CoV-2 Vaccines","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-12-10","conditions":"Vaccine Adverse Reaction","enrollment":580},{"nctId":"NCT05113472","phase":"","title":"Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers","status":"COMPLETED","sponsor":"Respiralab","startDate":"2021-03-01","conditions":"Adverse Drug Event","enrollment":1291},{"nctId":"NCT04993560","phase":"","title":"Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-07-18","conditions":"SARS-CoV 2 Infection, Covid19","enrollment":305},{"nctId":"NCT04900467","phase":"NA","title":"Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-28","conditions":"Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose","enrollment":418},{"nctId":"NCT04865900","phase":"","title":"Prevalence of Perimyocarditis After Covid-19 Vaccine","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2021-03-09","conditions":"Perimyocarditis, Covid19","enrollment":500},{"nctId":"NCT04844632","phase":"","title":"COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-02-11","conditions":"Health Care Utilization, Health Care Associated Infection","enrollment":5000},{"nctId":"NCT04706156","phase":"","title":"Oral Side Effects of COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Masaryk University","startDate":"2021-01-27","conditions":"Oral Manifestations, Covid19, Vaccine Adverse Reaction","enrollment":1540}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cominarty"],"phase":"marketed","status":"active","brandName":"BioNTech - Pfizer COVID-19 vaccine","genericName":"BioNTech - Pfizer COVID-19 vaccine","companyName":"University of Birmingham","companyId":"university-of-birmingham","modality":"Biologic","firstApprovalDate":"","aiSummary":"This mRNA vaccine instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response that protects against COVID-19 infection. Used for COVID-19 prevention in individuals 6 months of age and older, COVID-19 booster vaccination.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}